Early anti-PD1 therapy before surgery in high-risk stage II melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an ambispective observational cohort study using data from routine clinical care to compare outcomes between patients who started anti-PD1 therapy before surgery and those who followed the standard timing. No treatments are assigned by the study; all decisions are made by treating physicians. Outcomes of interest include recurrence-free survival, overall survival, and pathological response, analyzed descriptively. The retrospective arm reflects standard practice after surgery, while the prospective arm includes patients who began anti-PD1 therapy prior to surgery. Eligible adults with histologically confirmed cutaneous melanoma at high risk are included, with outcomes tracked in routine follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Adults (≥18 years) with histologically confirmed cutaneous melanoma stage IIB or IIC or stage III (N1c), managed in routine clinical practice.

Exclusion Criteria:

* Patients without sufficient clinical or follow-up data.
* Patients who do not provide informed consent (for prospective cohort).

Where it's running

• AC Camargo Cancer Center
  São Paulo, São Paulo, Brazil Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Guiding melanoma surgery in children using pathology and genetics

  This pediatric phase 2 trial tests whether using tumor pathology and genetic information to classify risk can guide safer, more appropriate surgery for localized skin melanocytic tumors.

  Recruiting at 13 sites Phase 2 Children's Oncology Group · Oakland, California and 12 other locations · NCT07621614

• First-in-human test of KUP-101A in selected advanced skin cancers

  This early study tests KUP-101A to see if it's safe and tolerable and to gather initial clues about its activity in patients with advanced skin cancers.

  Recruiting at 3 sites Phase 1 Kupando GmbH · Munich, Bavaria and 2 other locations · NCT07600476

• Phase 1 of PF-08046033 for advanced non-small-cell lung cancer, esophageal squamous cell cancer, and cutaneous melanoma

  This Phase 1 study will try the experimental antibody-drug conjugate PF-08046033 in adults whose non-small-cell lung cancer, esophageal squamous cell cancer, or cutaneous melanoma has progressed after standard treatments.

  Recruiting at 20 sites Phase 1 Pfizer · Denver, Colorado and 20 other locations · NCT07519655

• Work-related sun exposure and skin melanoma in the Modena area

  This project will see if people who work outdoors in the Modena area are more likely to develop types of melanoma linked to long-term sun exposure.

  Recruiting University of Modena and Reggio Emilia · Modena, Mo · NCT07251335

• Symptoms from immune checkpoint inhibitor therapy for cutaneous melanoma

  We will follow adults with stage IIB–IV cutaneous melanoma who are receiving immune checkpoint inhibitors to see how their symptoms change over time and which factors are linked to worse symptom patterns.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07148245

• Older adults with early-stage melanoma: WLE alone vs. WLE with SLN biopsy

  This trial tests whether doing wide local excision alone works as well as the standard approach of WLE plus sentinel lymph node biopsy for older adults with early-stage melanoma.

  Recruiting at 176 sites Phase 3 Eastern Cooperative Oncology Group · Birmingham, Alabama and 180 other locations · NCT07068074

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.